| Bioactivity | PA452, retinoic X receptor (RXR) specific antagonist, inhibits the effect of Retinoic acid (RA) on Th1/Th2 development[1]. | ||||||||||||
| Invitro | PA452 inhibits the Troglitazone (TZ)-induced CK13 expression[2].PA452 (0.01, 0.1, and 1 μM) inhibits RXR in normal human urothelial (NHU) cells[2]. | ||||||||||||
| Name | PA452 | ||||||||||||
| CAS | 457657-34-0 | ||||||||||||
| Formula | C26H37N3O3 | ||||||||||||
| Molar Mass | 439.59 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Iwata M, et al. Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors. Int Immunol. 2003 Aug;15(8):1017-25. [2]. Varley CL, et al. Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. Am J Pathol. 2004 May;164(5):1789-98. |